Hepatitis B virus (HBV)
infection is a major global health problem with no established cure. Dedicator of cytokinesis 11 (DOCK11), known as a
guanine nucleotide exchange factor (GEF) for Cdc42, is reported to be essential for the maintenance of HBV. However, potential therapeutic strategies targeting DOCK11 have not yet been explored. We have previously developed an in vitro virus method as a more efficient tool for the analysis of proteomics and evolutionary
protein engineering. In this study, using the in vitro virus method, we screened and identified a novel antiasialoglycoprotein receptor (ASGR) antibody, ASGR3-10M, and a DOCK11-binding
peptide, DCS8-42A, for potential use in HBV
infection. We further constructed a fusion
protein (10M-D42AN) consisting of ASGR3-10M, DCS8-42A, a fusogenic
peptide, and a
nuclear localization signal to deliver the
peptide inside hepatocytes. We show using immunofluorescence staining that 10M-D42AN was endocytosed into early endosomes and released into the cytoplasm and nucleus. Since DCS8-42A shares homology with activated cdc42-associated
kinase 1 (Ack1), which promotes EGFR endocytosis required for HBV
infection, we also found that 10M-D42AN inhibited endocytosis of EGFR and Ack1. Furthermore, we show 10M-D42AN suppressed the function of DOCK11 in the host DNA repair system required for covalently closed
circular DNA synthesis and suppressed HBV proliferation in mice. In conclusion, this study realizes a novel hepatocyte-specific drug delivery system using an anti-ASGR antibody, a fusogenic
peptide, and DOCK11-binding
peptide to provide a novel treatment for HBV.